Evidence map›Paper›PMID 39570746›Full record

ArticleCell reports2024

ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer.

Benedetto DiCiaccio, Marco Seehawer, Zheqi Li, Andriana Patmanidis, Triet Bui, Pierre Foidart, Jun Nishida, Clive S D'Santos, Evangelia K Papachristou, Malvina Papanastasiou and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Discovery and structural studies of histone demethylases.Frontiers in epigenetics and epigenomics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Benedetto DiCiaccioDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Marco SeehawerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Zheqi LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Andriana PatmanidisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Triet BuiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Pierre FoidartDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Jun NishidaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Clive S D'SantosCambridge Research Institute, University of Cambridge, Cambridge, UK.
Evangelia K PapachristouCambridge Research Institute, University of Cambridge, Cambridge, UK.
Malvina PapanastasiouThe Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA.
Andrew H ReiterThe Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA.
Xintao QiuCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Rong LiCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yijia JiangCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Xiao-Yun HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Anton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Stephen C KalesNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Ganesha RaiNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Madhu Lal-NagNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Ajit JadhavNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Jason S CarrollCambridge Research Institute, University of Cambridge, Cambridge, UK.
Henry W LongCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Ludwig Center at Harvard, Boston, MA 02115, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.

Funding

Targeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4M
Tissue and Pathology CoreP01CA250959 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2020 to 2024
$8.6M
Cancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6M
NCI NIH HHS P01 CA250959NCI NIH HHS R35 CA197623NCI NIH HHS T32 CA236754
6 · The paper itself

Abstract

We previously described that the KDM5B histone H3 lysine 4 demethylase is an oncogene in estrogen-receptor-positive breast cancer. Here, we report that KDM5A is amplified and overexpressed in basal breast tumors, and KDM5 inhibition (KDM5i) suppresses the growth of KDM5-amplified breast cancer cell lines. Using CRISPR knockout screens in a basal breast cancer cell line with or without KDM5i, we found that deletion of the ZBTB7A transcription factor and core SAGA complex sensitizes cells to KDM5i, whereas deletion of RHO-GTPases leads to resistance. Chromatin immunoprecipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq) revealed co-localization of ZBTB7A and KDM5A/B at promoters with high histone H3K4me3 and dependence of KDM5A chromatin binding on ZBTB7A. ZBTB7A knockout altered the transcriptional response to KDM5i at NF-κB targets and mitochondrion-related pathways. High expression of ZBTB7A in triple-negative breast cancer is significantly associated with poor response to neoadjuvant chemotherapy. Our work furthers the understanding of KDM5-mediated gene regulation and identifies mediators of sensitivity to KDM5i.

Indexed as

Breast NeoplasmsDNA-Binding ProteinsGene Expression Regulation, NeoplasticTranscription FactorsAnimalsCell Line, TumorFemaleGene Regulatory NetworksHistonesHumansNF-kappa BPromoter Regions, GeneticRetinoblastoma-Binding Protein 2DNA-Binding ProteinsHistonesKDM5A protein, humanNF-kappa BRetinoblastoma-Binding Protein 2Transcription FactorsZBTB7A protein, humanbreast cancerCP: CancerCRISPR screenhistone demethylasemitochondrial signaling

Identifiers

PMID39570746
PMCPMC11694571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.